Kornimate/medical-research-clean huggingface dataset:
pilates effect on women with and without obesity

Conditions: Obesity Prevention; Obesity and Overweight; Exercise; Pilates Exercise

Summary: obesity, a health problem, is caused by insufficient physical activity and unhealthy nutrition. for individuals with obesity, non-weight-bearing and enjoyable exercises, such as pilates, should be implemented as physical activity due to potential pain. this study aims to examine the effects of an 8-week pilates exercise program on body composition, posture, and psychosocial parameters in individuals with and without obesity. methods: the study included 58 female participants: 30 individuals with obesity (npilates = 15; ncontrol = 15) and 28 individuals without obesity (npilates = 14; ncontrol = 14). participants performed pilates exercises twice a week for 8 weeks. body mass index (bmi), body fat percentage (bfp), and posture scores were calculated, and from a psychosocial perspective emotional eating scale (ee), social physique anxiety inventory (spa), and self-esteem scales (se) were administered before and after the eight weeks.

there are no studies in the literature examining the effects of pilates exercises on emotional eating and posture. additionally, there are no studies examining the effects of pilates on posture in individuals with obesity. most studies in the literature have focused on sedentary women; however, no study has specifically examined the effects of pilates-based exercises on individuals with and without obesity. this study aims to investigate the effects of an 8-week pilates intervention on postural alignment, bmi, fat percentage, and psychosocial parameters (emotional eating, social physical anxiety, and self-esteem) in individuals with and without obesity. thus, this study will provide valuable insights into the role of pilates in weight management, posture correction, and psychosocial well-being among individuals with and without obesity. the study included 58 female participants: 30 individuals with obesity (npilates = 15; ncontrol = 15) and 28 individuals without obesity (npilates = 14; ncontrol = 14). participants performed pilates exercises twice a week for 8 weeks. body mass index (bmi), body fat percentage (bfp), and posture scores were calculated, and from a psychosocial perspective emotional eating scale (ee), social physique anxiety inventory (spa), and self-esteem scales (se) were administered before and after the eight weeks.

Eligibility criteria:
inclusion criteria: * being a sedentary individual and not not doing regular physical activity * being 20 years old or older * having a bmi of 30 kg/m² or above for inclusion in the group of women with obesity. * having a bmi below 30 kg/m² for inclusion in the group of women without obesity. * not having any health problems that would prevent participation in exercise. * not having undergone surgery affecting the musculoskeletal system within the last year. exclusion criteria: * voluntary withdrawal from the study. * failure to comply with the required procedures of the study. * arbitrary disruption of the exercise schedule more than twice.

Keywords: exercise obesity health physical fitness psychology
evaluate the pharmacokinetics, safety, and tolerability of alisporivir in subjects with hepatic impairment compared to healthy subjects

Conditions: Hepatic Insufficiency

Summary: this is an open-label study to evaluate the pharmacokinetics, safety and tolerability of single oral doses of alisporivir in subjects with mild and moderate hepatic impairment compared to matched healthy subjects with normal liver function.


Eligibility criteria:
inclusion criteria: * male or female, 18 to 70 years of age, in good health * stable child-turcotte-pugh score of at least 5 * body weight of at least 50 kg and a bmi of 18.0 to 36.0 kg/m2 exclusion criteria: * use of other investigational drugs * women of child-bearing potential other protocol-defined inclusion/exclusion criteria may apply

Keywords: hepatic impairment mild and moderate hepatic impairment alisporivir
optimization of cardioprotection in diabetic patients undergoing cardiac surgery

Conditions: Myocardial Ischemia

Summary: this study evaluates the myocardial protection against perioperative ischemia comparing two standard anesthetic regimes in diabetic patients undergoing elective cardiac surgery. half of the patients will receive volatile anesthesia while the other half will receive total intravenous anesthesia. primary and secondary outcome parameters will be assessed after induction of anesthesia, at the end of the procedure and postoperative day 1 to 3.

volatile anaesthetics such as sevoflurane have shown to have a protective effect regarding myocardial ischemia in the perioperative setting - the so-called "preconditioning". however the observed response of preconditioning in clinical trials is not consistent. an increased perioperative insulin resistance especially in diabetic patients resulting in an increased postoperative morbidity and mortality may be responsible for these findings. in an animal model, the use of propofol that is being routinely applied for general anesthesia was associated with a change of the insulin receptor substrate via phosphorylation and thus a change of insulin resistance. avoiding a total intravenous anesthesia and applying a volatile anesthesia may result in an increased cardioprotective effect by a reduction of the perioperative insulin resistance.

Eligibility criteria:
inclusion criteria: * diabetes * elective cardiac surgery exclusion criteria: * emergency procedures * preop myocardial infarction * preop cardiac failure * preop renal replacement therapy

Keywords: ischemia cardiac surgery volatile anesthetic total intravenous anesthesia
external device for erectile dysfunction (3d-erect)

Conditions: Erectile Dysfunction; Impotentia Erigendi

Summary: the aim of this clinical trial is to test the safety and feasibility of a non-invasive 3d-printed external penile device to achieve successful and satisfactory sexual intercourse in men with erectile dysfunction (ed).

a clinical trial to test the safety and feasibility of our newly developed non-invasive 3d-printed external penile device for the treatment and recovery of erectile dysfunction.

Eligibility criteria:
inclusion criteria: * males \>18 years old suffering from any cause moderate to severe erectile dysfunction (e.g. ed after radical prostatectomy and/or radiation therapy for prostate cancer and or other pelvic malignancies affecting the sexual potency; emotional and psychological ed; organic vascular and/or metabolic ed etc.) * having a female partner willing to participate in the study. exclusion criteria: * not willing to attempt sexual vaginal intercourse with their partner * inability to wear/operate the external penile device for any reason
comparison of pain relief between high thoracic erector spinae plane block and cervical epidural injection

Conditions: Pain, Chronic

Summary: the primary endpoint of this study was to identify whether there is a pain improving effect of high thoracic eretor spinae plane block (espb) when compared with cervical epidural injection

the erector spinae plane block (espb) is a less invasive, safer, and technically easy alternative procedure to conventional neuraxial anesthetic techniques. in contrast to common neuraxial techniques such as paravertebral and epidural injections, the espb targets an interfascial plane which is far from the spinal cord, root, and pleura. first applied to thoracic neuropathic pain, currently espb is being applied to postoperative pain control and includes variable clinical situations. in the abdomen and thoracic wall, thoracic espb can be applied for pain control after cardiac surgery, video-assisted thoracic surgery, laparoscopic cholecystectomy, and thoracotomy. recently, favorable postoperative pain control after lumbar spinal or lower limb surgeries has been reported with lumbar espb. in addition, espb has also been used for chronic pain conditions in the upper and lower extremities. to investigate the possible mechanism of action of the espb, many previous studies have focused on examining the physical spread of the injected agent. commonly, contrast dye injections in human cadavers have been utilized to assess the spread level. physical spread level was determined using various methods including direct dissection or sectioning, computed tomography (ct), thoracoscopic inspection, or magnetic resonance imaging (mri) with radiocontrast injection. apart from human cadaver studies, physical spread level has been evaluated in alive patients using a variable volume of local anesthetics mixed with radiocontrast. however, these studies are limited by the small number of included patients.

Eligibility criteria:
inclusion criteria: * cervical spinal stenosis * cervical intervertebral disc herniation * cervical facet arthropathy * cervical foraminal stenosis exclusion criteria: * allergy to local anesthetics or contrast medium * pregnancy * spine deformity * patients with coagulation abnormality

Keywords: pain, lumbar
safety and effectiveness of giving su5416 to hiv-infected patients with aids-related kaposi's sarcoma

Conditions: Sarcoma, Kaposi; HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give su5416 to hiv-infected patients with aids-related kaposi's sarcoma (ks). su5416 may prevent the growth of ks tumors.

groups of 3-6 patients are sequentially assigned to receive escalating doses of su5416 in 33% increments. study drug is administered as a twice-weekly intravenous injection for 4 weeks. in the absence of unacceptable toxicity, responding patients may continue on su5416 in 4-week treatment cycles for a maximum of 1 year or until the presence of unacceptable toxicity or tumor progression.

Eligibility criteria:
inclusion criteria you may be eligible for this study if you: * are at least 18 years old. * are hiv-positive. * have ks with at least 5 skin lesions. * have been in stable condition for at least 6 weeks prior to study entry, if receiving antiretroviral therapy. * agree to use effective methods of birth control during the study. exclusion criteria you will not be eligible for this study if you: * have had surgery within 4 weeks of study entry. * have taken certain medications, including therapy for ks, within 3 weeks prior to study entry. * have pulmonary ks (ks in your lungs). * have certain serious medical conditions, including liver or kidney problems, certain infections, and certain cancers. * are allergic to cremophor. * have not recovered from previous cancer treatment (chemotherapy, radiotherapy, or immunotherapy). * are pregnant.

Keywords: skin neoplasms sarcoma, kaposi antineoplastic agents
anti-tnf-alpha trough level measurements in inflammatory bowel disease

Conditions: Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis

Summary: drug serum concentrations will be measured at several time-points for inflammatory disease patients treated with anti-tnf agents. the purpose is to determine which patients that will clinically benefit from either discontinue treatment, adjusting the dose, switch to another anti-tnf agent or a different class of medication.

crohn´s disease and ulcerative colitis are diseases where the proinflammatory cytokine tumor necrosis factor-alpha (tnf) plays an important role. anti-tnf agents are used in the treatment. however, some patients do not respond and response rates declines over time. the cause may be immunogenicity against the agent itself, the agent´s failure to neutralize tnf or another biological pathway leading to inflammation. anti-tnf agents have been administrated as fixed doses at certain frequencies and this may not be optimal for all patients, but recent studies have indicated a correlation between efficacy and serum drug concentration levels (trough levels). our preliminary data suggest that trough levels early in the treatment course may be predictive of later trough levels. by multiple measurements, this will be assessed. the study will also investigate biological markers in serum and blood cells which may be predictable for trough levels. finally, we will compare different methods to measure serum drug concentrations.

Eligibility criteria:
inclusion criteria: * patients diagnosed with inflammatory bowel disease * treated with anti-tnf drug * follow-up at specialized gastroenterologist in norway * age 18 or over exclusion criteria: * patients refusing to participate by not giving their informed consent

Keywords: antibodies, monoclonal anti-tnf tnf-alpha trough level drug concentration elisa
efficacy of bfr training combined with eccentric exercise as assessed by swe in subjects with chronic at

Conditions: Achilles Tendinopathy

Summary: the purpose of this randomized controlled trial is to use shear wave elastography (swe) to assess achilles tendinopathy and the effectiveness of blood flow restriction (bfr) training in patients with achilles tendinopathy as measured by numeric pain rating scale, functional self-report, and objective functional measures. swe will be utilized to objectively quantify tendon properties and bfr training and eccentric exercise will be utilized to treat achilles tendinopathy.


Eligibility criteria:
inclusion criteria: * achilles pain for \> 3 months * unilateral symptoms only * dod beneficiary, between the ages of 18 and 65 * clinical diagnosis of achilles tendinopathy * read and speak english well enough to provide informed consent and follow study instructions. * can attend in-clinic treatments 2-3 x weekly for the next 12 weeks exclusion criteria: * any disease or disease process that would preclude the participant from safely performing any of the exercises or intervention at the discretion of the pi. (uncontrolled diabetes, cardiac disease, severe copd, open wounds, current infection, etc.) * any le surgery on either side in the last 2 years * history of achilles rupture * any vascular disorder (varicose veins, hx of dvt) * leaving post/station in the following 3 months precluding them being able to come in for f/u visits * self-report of pregnancy (currently or within last 6 months) * other foot/le disorder that prevents the completion of the eccentric exercises or bfr exercise * unable/unwilling to hop on symptomatic leg * pain \< 2/10 of average pain on nprs * visa a score \> 80% * currently going through meb/worker's comp
treatpacs = treatment for preschool age children who stutter

Conditions: Stuttering, Developmental

Summary: treatment for preschool age children who stutter: a randomised, multicentre, non-inferiority parallel group pragmatic trial with mini-kids, the social cognitive behaviour therapy and the lidcombe program with 249 children

three treatment approaches for preschool age children who stutter are delivered and %syllables stuttered at 18 months post-randomisation of the three arms are compared . mini-kids is a direct treatment based on principles of stuttering modification, with pseudo-stuttering, that is, deliberate stuttering, as one of the main components. the program for 4-6-year old children consists of four stages: stage 1 = desensitization, stage 2 = modification, stage 3 = identification and stage 4 = generalization. the program for 2-4-year old children does not include stage 3. speech therapist and parent(s) are the speech model for the child. they add normal dysfluencies to their speech. later on in treatment and if necessary, children learn to recognise and alter their stuttering moments. the social cognitive behaviour therapy contains 5 treatment phases: (1) conditioning speaking activities, (2) cognitive training focused on emotions, (3) cognitive training focused on cognitions, (4) emotional training and (5) skill training (boey, 2010). this treatment is not directed at the speech of the children, but rather at the cognitive and emotional aspects that surround the stuttering. the lidcombe program (lp) is an operant program that directly provides verbal feedback to the child's stutter-free speech (mainly) and the child's stuttering (occasionally). the program comprises two stages: stage 1 in which (near) zero levels of stuttering are achieved and stage 2 in which the achieved (near) zero levels of stuttering are maintained for a long period of time. the lp usually takes between 11 to 23 (60-minute) treatment sessions to achieve the goals of stage 1, i. e. (near) zero levels of stuttering.

Eligibility criteria:
inclusion criteria: preschool age children must * stutter (identified by the speech-language therapist) * be aged between 2 - 6.5 years * have normal hearing reported by the parent(s) * have, if bilingual, a parent who speaks a language that the slt understands and speaks to allow clear communication * have at least one parent agreeing to be intensively involved in treatment and knowing that s/he will implement treatment at home * have at least one parent who is willing and able to videorecord his/her child regularly exclusion criteria: - have a syndrome such as down syndrome.
the effect of sugar load in ibs patients depending on sucrase-isomaltase genes

Conditions: Sucrase-Isomaltase Deficiency; Irritable Bowel Syndrome

Summary: the investigators know that many patients with irritable bowel syndrome (ibs) have functional variants of genes coding for sucrase-isomaltase enzymes. the investigators will now examine whether these functional variants are associated with defect degradation of sucrose and associated gastrointestinal symptoms

the investigators have in a previous study included ibs patients for treatment with a starch- and sucrose reduced diet (ssrd). the investigators found a great improvement of symptoms. the investigators gene-tested those patients, and now have the full identification of all functional variants encoding sucrase-isomaltase enzymes. the investigators will invite patients from this previous study with normal genes and functional variants of genes. the patients will come fasting over night to the department of clinical research. the participants will ingest 75 g sugar dissolved in 0.8 dl water and flavored with lemon, to ingest during 5 minutes. after that, glucose will determined repeatedly up to 2 hours afterwards. at the same time, the participants have to assess their gastrointestinal sympotms on visual analogue scales (vas). the investigators will compare the raise in b-glucose and symptoms between the groups of patients, divided into gene expression.

Eligibility criteria:
inclusion criteria: * participants of our previous clinical trial with ssrd diet (nct03306381) exclusion criteria: * difficulties in taking blood samples

Keywords: gastrointestinal symptoms, glucose
fast-fish -food allergy specific treatment for fish allergy.

Conditions: Fish Allergy

Summary: the aim of this study is to investigate the safety and tolerability of subcutaneous immunotherapy treatment (scit) with incremental doses of a modified recombinant fish parvalbumin (mcyp c 1) quantified in mass units: to establish a safe dose of the candidate hypo-allergen in human subjects and to study the pharmaco-dynamics of the hypo-allergen administered to human subjects. the study is performed as a placebo-controlled double-blinded randomized trial with 24 fish allergic patients allocated into three different groups of eight.

the aim of the fast project in general is to develop novel recombinant allergen-based therapeutics for the treatment of food allergy. the chosen approach is to modify recombinant allergens into hypo-allergenic molecules to decrease the risk of anaphylactic side-effects and to allow administration of higher doses leading to better efficacy.

Eligibility criteria:
inclusion criteria: * male or female subject from 18 to 65 years old and in general good health as determined by past medical history and physical examination. * case history of allergy to fish ingestion. * specific ige to fish by either a positive spt to cod fish extract or an immunocap to cod fish above 0.70 kua/l,(class 2) at screening. * positive double blind placebo-controlled food challenge (dbpcfc) with fish within the last two years. * fev1 at least 80% of predicted values at screening. * subject accepting to comply fully with the protocol. * for woman of child bearing potential: * a negative urine pregnancy test at screening visit, * subject must receive a medically effective contraceptive method during the study exclusion criteria: * food anaphylactic reaction: anaphylactic shock due to fish intake. * specific ige (immunocap) to fish parvalbumin (rcyp c 1) below 0.35 kua/l * ongoing pollen immunotherapy (sit). * any clinical condition that contraindicates sit (eaaci-guidelines). * any significant clinical condition that the investigators judged might hamper the patient's safety or the study outcomes, these diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, immunological and endocrine disease. * ongoing treatment with betablockers or ace-inhibitors. * impossibility for the patient to comply with the scheduled visits. * pregnancy or nursing. * uncontrolled asthma. * subject who have participated in a clinical trial within 3 months prior to this one. * subject with a history of drug or alcohol abuse. * investigators, co-investigators, as well as their children or spouses and all the study collaborators should not be enrolled in the study. * patients with concurrent allergy symptoms can be included if patients can manage without antihistamines during screening and treatments.

Keywords: fish allergy immunotherapy hypoallergen
a retrospective data collection study in patients receiving dexamethasone intravitreal implant (ozurdex®) for macular oedema due to retinal vein occlusion (rvo)

Conditions: Macular Edema

Summary: this study will use retrospective data to evaluate the efficacy, safety, and re-injection interval of ozurdex® in the treatment of macular oedema due to retinal vein occlusion (rvo).


Eligibility criteria:
inclusion criteria: * macular oedema in the study eye due to brvo or crvo * received at least 2 ozurdex® injections in the study eye exclusion criteria: * received ozurdex® injections as part of or during any clinical study